Internal medicine
-
Comparative Study
Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis.
We attempted to evaluate the feasibility (therapeutic efficacy, tolerance, and clinical courses after treatment) of pirfenidone, an anti-fibrotic drug for patients with chronic pulmonary fibroses such as idiopathic pulmonary fibrosis (IPF). ⋯ The feasibility of Pirfenidone as a therapeutic drug was confirmed for patients with advanced pulmonary fibrosis.
-
Editorial Comment
Headache and spontaneous vertebral artery dissection.